Sagimet Biosciences

rocket snail slow leapfrog beat fast win jump over
Biotech

As Madrigal lands MASH nod, what's next for biotechs in pursuit?

Madrigal’s MASH drug has been approved. For the other companies with up-and-coming treatments trailing in the clinic, the question is: What now?
Annalee Armstrong Mar 15, 2024 10:55am
rocket blast off sky rocket space clouds

Sagimet stock doubles as phase 2b MASH trial hits primary goals

Jan 22, 2024 10:30am
Non-alcoholic fatty liver disease

Sagimet's NASH drug-GLP-1 combo tops either alone for fibrosis

Nov 29, 2023 8:06pm
Wall Street stock exchange finance shares share price Nasdaq

Apogee, Sagimet overshoot IPO expectations as they reach Nasdaq

Jul 14, 2023 8:55am
water thaw

2 biotechs test icy IPO waters with $228M and $66M offerings

Jul 10, 2023 11:43am
parachute

Frazier departs Merck after 30 years—Chutes & Ladders

Oct 28, 2022 9:30am